glp-1 obesity drug news today 2025 A nice article in The Hindu today highlights the FDA says that the GLP-1
Description
In the LIVE trial, liraglutide had no meaningful impact on SBP or left ventricular function in HFrEF but increased heart rate by approximately 7 beats per minute
The pharmacokinetics of sitagliptin was generally similar in healthy subjects and in patients with type 2 diabetes
Risk-benefit discussion of medication options
Bucciarelli, G
GLP1RAs significantly decreased E-wave velocity, E/A ratio, E/e _ ratio, and EDT but did not affect LVEF
Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation
